Finvest
TAK Pharmaceuticals · Large cap · Japan · Drug pipeline · Thesis updated July 20, 2026

Takeda's transition is starting to work

01 Running thesis

A cleaner handoff

Takeda is in the middle of a hard handoff. Older products are fading, led by VYVANSE after generic copies entered the market. At the same time, newer medicines are growing and now carry more than half of company revenue.

The thesis has improved. Management said the VYVANSE hit peaked in the first half of FY2025, and later said cost control fully offset the profit impact. That matters because it gives Takeda more room to fund launches without letting margins fall apart.

ENTYVIO is the key bridge. The Pen version now has access with all three large U.S. pharmacy benefit managers, with more than 80% commercial coverage. That should help U.S. growth stabilize after earlier payer access problems.

The bull case rests on the pipeline. Oveporexton and rusfertide have been filed with the FDA, and zasocitinib is in filing prep. If those launches work, they can help offset ENTYVIO biosimilar pressure later in the 2030s. If they stumble, Takeda may look more like a slow-growth drug company with debt and patent cliffs.

May 2026▲Takeda gave more detail on the transition plan, with three major launch candidates expected within 12 months. The update also showed the cost of the reset, including about 4,500 affected roles and JPY 170 billion of expected restructuring cost.
Jan 2026▲ENTYVIO Pen access improved sharply, reaching all three large U.S. PBMs and more than 80% commercial coverage. Management also said OpEx discipline fully offset the VYVANSE impact, while Albumin softness in China became a new watch item.
Oct 2025→The VYVANSE generic hit appeared past its peak, but ENTYVIO growth expectations and foreign exchange both weighed on the near-term outlook. Takeda also stopped its cell therapy work and added Innovent oncology assets.
May 2025→Takeda entered the final year of major VYVANSE erosion while facing a JPY 130 billion U.S. rebate headwind. Positive rusfertide Phase 3 data strengthened the pipeline case.
Jan 2025▲Guidance improved as Growth & Launch products stayed strong and VYVANSE erosion was slower than expected. Takeda also announced a JPY 100 billion buyback and a planned CEO transition for June 2026.
Oct 2024▲The initial view was built around strong Growth & Launch momentum, ENTYVIO Pen traction, and a multi-year efficiency program. VYVANSE was already declining, but less sharply than feared.
02 Business model

Patents fund the pipeline

Takeda makes money by selling prescription drugs, vaccines, and plasma-derived therapies. Many of its best products are protected by patents, special manufacturing know-how, or strong doctor use. When protection ends, generic or biosimilar rivals can take share and cut prices fast.

The company is trying to replace older revenue with Growth & Launch products. That group grew 6.7% at constant exchange rates in Q3 and includes ENTYVIO, newer rare disease drugs, oncology drugs, QDENGA, and other launch assets.

Cost cuts are a major part of the model right now. Management is using an enterprise-wide efficiency program and expects core operating profit margins to improve by 100 to 250 basis points annually from FY2025. A basis point is one one-hundredth of a percentage point.

There is a tradeoff. Takeda is cutting costs while also preparing major launches. In FY2026, management expects about 4,500 roles to be affected by the transformation and expects JPY 170 billion of restructuring cost. The plan works only if savings do not weaken launch execution.

03 Product portfolio

What carries the story

Growth engine

ENTYVIO

ENTYVIO treats inflammatory bowel disease. Its Pen version now has more than 80% U.S. commercial coverage, which reduces a key access risk.

Cash cow

VYVANSE

VYVANSE treats ADHD and is now facing generic erosion. Takeda lost about JPY 150 billion of VYVANSE revenue in FY2025, but management says the worst pressure is tapering.

Steady

Plasma-Derived Therapies

This business sells therapies made from human plasma, including immunoglobulin products. Subcutaneous immunoglobulin is growing well, but Albumin demand in China is softer than expected.

Option

QDENGA

QDENGA is Takeda's dengue vaccine. It grew 22.1% in Q3, driven mainly by Brazil, but currency moves can hurt reported profit.

Option

Oveporexton

Oveporexton is a late-stage narcolepsy type 1 drug candidate. Takeda has filed a new drug application with the FDA.

Option

Rusfertide

Rusfertide is aimed at polycythemia vera, a blood disorder. Its FDA filing is submitted after positive Phase 3 data.

Option

Zasocitinib

Zasocitinib is a psoriasis drug candidate in filing prep. It is part of the next launch wave that needs to offset older product erosion.

04 Business segments

Where revenue comes from

Gastroenterology31%modest
Plasma-Derived Therapies24%modest
Rare Diseases17%modest
Oncology13%modest
Neuroscience9%declining
Vaccines1%growing fast
Other5%declining

The mix uses FY2025 business-area revenue for the year ended March 31, 2026. Gastroenterology is the largest area, while Neuroscience is shrinking because of VYVANSE generic competition.

05 Risk factors

What could break it

ENTYVIO competition

High impact · Medium odds

ENTYVIO is central to Takeda's bridge from old drugs to new launches. Biosimilar rivals, which are close copies of biologic drugs, are an emerging risk in Europe. Takeda points to patents that run into 2032, but filings by rivals make this a live issue.

We watchWatch European biosimilar approvals, launch dates, and ENTYVIO growth in Crohn's disease.

Launch cycle execution

High impact · Medium odds

Oveporexton, rusfertide, and zasocitinib carry a large part of the bull case. Two FDA filings are submitted, but approval, labeling, pricing, and doctor adoption still have to go right. A weak launch would leave Takeda more exposed to ENTYVIO and VYVANSE pressure.

We watchWatch FDA acceptance, approval decisions, launch timing, labels, and first-year sales.

Albumin softness in China

Medium impact · Medium odds

Takeda's plasma business is mixed. Subcutaneous immunoglobulin is growing strongly, but Albumin returned to only 1.3% growth in Q3 and was slower than expected because demand in China softened. If that weakness lasts, PDT may finish below forecast.

We watchWatch Albumin growth, China demand commentary, and PDT full-year guidance.

U.S. pricing pressure

Medium impact · High odds

U.S. Medicare Part D redesign and 340B expansion create near-term gross-to-net pressure, meaning more rebates and discounts come off list prices. Management previously quantified a JPY 130 billion impact from these U.S. rebate changes. The longer-term IRA drug pricing rules may add more pressure.

We watchWatch U.S. gross-to-net commentary, IRA drug selection lists, and changes in Medicare exposure.

Currency and tariff drag

Medium impact · Medium odds

Takeda reports in yen but sells and spends across many currencies. In FY2025, transactional foreign exchange hurt core operating profit, especially around QDENGA. Tariff risk looks smaller because U.S. imports are about 8% to 10% of U.S. revenue, but trade policy can still change.

We watchWatch euro and yen moves, QDENGA profit commentary, and U.S. tariff rules for drug imports.
06 Quick answers

In one breath

Why is Takeda stock tied to VYVANSE?

VYVANSE used to be a major profit source, but generic versions are now taking share. The good news for Takeda is that management says the sharpest part of the erosion has passed.

What is Takeda's most important drug?

ENTYVIO is the key product to watch because it is large, still growing, and central to the transition plan. Its U.S. Pen access has improved, but future biosimilar competition is a major risk.

What are Takeda's next big launches?

The main late-stage launches are oveporexton for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis. Oveporexton and rusfertide have FDA filings submitted.